In 2023, the projected incidence rate of breast cancer in the Australian population was around *** cases per 100,000 in the ** to ** age group, an incidence rate higher than any other age group. In contrast, zero cases per 100,000 people were projected to be diagnosed amongst children aged 14 and below that year.

In 2024, the age-standardized mortality rate from breast cancer for women in Australia was estimated to be **** out of 100,000 women. The rate for men is significantly lower at *** out of 100,000 men.

This statistic shows the age-specific breast cancer mortality rate in Australia in 2016. That year, about ***** out of every 100,000 people aged 85 years or older in Australia died from breast cancer.

This dataset presents the footprint of participation statistics in BreastScreen Australia for women ages 50 to 74, by age group. The national breast cancer screening program, BreastScreen Australia began in 1991. It aims to reduce illness and death from breast cancer using screening mammography for early detection of unsuspected breast cancer in women. The data spans the years of 2014-2016 and is aggregated to Statistical Area Level 3 (SA3) geographic boundaries from the 2011 Australian Statistical Geography Standard (ASGS). Cancer is one of the leading causes of illness and death in Australia. Cancer screening programs aim to reduce the impact of selected cancers by facilitating early detection, intervention and treatment. Australia has three cancer screening programs: BreastScreen Australia National Cervical Screening Program (NCSP) National Bowel Cancer Screening Program (NBCSP) The National cancer screening programs participation data presents the latest cancer screening participation rates and trends for Australia's 3 national cancer screening programs. The data has been sourced from the Australian Institute of Health and Welfare (AIHW) analysis of National Bowel Cancer Screening Program register data, state and territory BreastScreen Australia register data and state and territory cervical screening register data. For further information about this dataset, visit the data source:Australian Institute of Health and Welfare - National Cancer Screening Programs Participation Data Tables. Please note: AURIN has spatially enabled the original data.

Australia Breast Cancer Market is projected to grow around USD 24.8 billion by 2031, at a CAGR of 12.5% during the forecast period.

In 2020, Australia/New Zealand was the region with the highest incidence rate of breast cancer worldwide, with around 95.5 new cases per 100,000 women. This statistic shows the age-standardized incident rate (new cases) of breast cancer among women worldwide, by region.

Australia Mammography Market size was valued at USD 285 Million in 2024 and is projected to reach USD 495 Million by 2032 growing at a CAGR of 7.1% from 2025 to 2032.

Australia Mammography Market Dynamics

The key market dynamics that are shaping the Australia mammography market include:

Key Market Drivers

Rising Breast Cancer Incidence: According to Cancer Council Australia, breast cancer is the most frequent cancer among Australian women, with roughly 20,000 new cases diagnosed each year. The rising incidence of breast cancer is increasing the demand for early detection via mammography screening.

Population cohort of women, unaffected and affected by breast cancer, to investigate aspects of breast cancer risk and other important women's health issues. Collection of epidemiological information, mammogram images, breast cancer pathology data. Participants donate DNA and archival breast tumours are collected. Annual registry linkage to confirm cancer diagnoses and mortality data.

This dataset presents the footprint of cancer incidence statistics in Australia for all cancers combined and the 5 top cancer groupings (breast - female only, colorectal, lung, melanoma of the skin and prostate) and their respective ICD-10 codes. The data spans the years 2006-2010 and is aggregated to Statistical Area Level 3 (SA3) from the 2011 Australian Statistical Geography Standard (ASGS).

Incidence data refer to the number of new cases of cancer diagnosed in a given time period. It does not refer to the number of people newly diagnosed (because one person can be diagnosed with more than one cancer in a year). Cancer incidence data come from the Australian Institute of Health and Welfare (AIHW) 2012 Australian Cancer Database (ACD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Cancer Database 2012 Data Quality Statement.

Please note:

• AURIN has spatially enabled the original data.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a SA3. The number of people who could not be assigned a SA3 is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• The ACD records all primary cancers except for basal and squamous cell carcinomas of the skin (BCCs and SCCs). These cancers are not notifiable diseases and are not collected by the state and territory cancer registries.

• The diseases coded to ICD-10 codes D45-D46, D47.1 and D47.3-D47.5, which cover most of the myelodysplastic and myeloproliferative cancers, were not considered cancer at the time the ICD-10 was first published and were not routinely registered by all Australian cancer registries. The ACD contains all cases of these cancers which were diagnosed from 1982 onwards and which have been registered but the collection is not considered complete until 2003 onwards.

• Note that the incidence data presented are for 2006-2010 because 2011 and 2012 data for NSW and ACT were not able to be provided for the 2012 ACD.

The number of females who participated in a breast cancer screening program and there proportion of the relevant population, as well as the number of people diagnosed with breast cancer as a rate of those who participated, 2010-2011 (NSW, Vic, Qld, SA & WA). Source: Compiled by PHIDU based on data from BreastScreen NSW, BreastScreen Vic, BreastScreen Qld, BreastScreen WA - 2010 and 2011.The Dataset also contains the number of females who participated in a cervical cancer screening program and there proportion of the relevant population, as well as the number of the people diagnosed with low/high cervical cancer as a rate of those who participated, 2010-2011 (NSW, Vic, Qld, SA, WA & ACT). Source: Compiled by PHIDU based on data from the NSW Department of Health and NSW Central Cancer Registry, 2011 and 2012; Victorian Cervical Cytology Registry, 2011 and 2012; Queensland Health Cancer Services Screening Branch, 2011 and 2012; SA Cervix Screening Program, 2011 and 2012; Western Australia Cervical Cytology Register, 2011 and 2012; and ACT Cytology Register, 2011 and 2012.For both sets of screening if a women was screened more than twice in the two year period she is counted once only (all entries that were classified as not shown, not published or not applicable were assigned a null value; no data was provided for Maralinga Tjarutja LGA, in South Australia). The data is by LGA 2015 profile (based on the LGA 2011 geographic boundaries). For more information on statistics used please refer to the PHIDU website, available from: http://phidu.torrens.edu.au/

Around ** in every 100,000 Australians were projected to be diagnosed with melanoma, a type of skin cancer, in 2023. The incidence rate increased with age, with the *****-year-old age group having an estimated incidence of over *** cases per 100,000 persons in 2023.

Incidence of cancer in Australia

Cancer incidence refers to the number of newly diagnosed cases of the disease in a particular time period, typically one year. Cancer is among the leading causes of illness and death in Australia. The types of cancer with the highest incidence in Australia include prostate, breast, colorectal/bowel, melanoma, and lung cancer.

The dark side of the sunny life Down Under

Australia and New Zealand are home to the highest incidence rates of melanoma in the world. Melanoma is a type of skin cancer that is commonly, however not exclusively, found on sun-exposed parts of the body, as the risk of developing melanoma increases with ultra-violet radiation (UV rays). Other types of skin cancers exist, however, melanoma is considered to be the most dangerous given its likelihood of spreading within the body.

To develop a new and unique geodatabase to identify locational disparities in population based breast cancer screening participation in South Australia according to place of residence. The small area geodatabase resulting from this project will provide a platform for advanced research into breast screening participation, geographic and spatial differentials in screening rates, and investigate possible predictors of these differentials. Specific analyses at the smallest geographic areas available will be undertaken where feasible to precisely identify social and demographic disparities and area level risk factors that warrant new service response.

Spatial analysis will be undertaken at the smallest area possible, ideally the statistical area 1 (SA1) level. In addition, we shall assess small area predictors of screening participation with measures that include age, education, socioeconomic status, ethnic composition, family status and housing, as well as screening service access (presence and distance to screening service). Changes in screening participation over time will be investigated and assessed in relation to variation in BreastScreen SA program delivery including service pathways and local availability and timing for mobile screening units.

The size of the Asia-Pacific Cancer Biomarkers Industry market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 12.50% during the forecast period. An Asia-Pacific Cancer Biomarkers Industry represents a developing industry, providing a lot of support to the detection and diagnosis of early treatment. A cancer biomarker is a specific type of molecule that includes proteins, genes, or metabolites that indicate cancer presence or progression in the body. Biomarkers are found within biological samples such as blood, urine, tissue, and other body fluids. The employment of cancer biomarkers has revolutionized the field of oncology because it leads to earlier and more accurate diagnosis of cancer. What had thus far been applied towards the diagnosis of cancer include imaging and biopsies, which are invasive and also take longer to produce results. Early detection of cancer through biomarkers can therefore benefit in terms of treatment outcomes or survival chances because the test is not invasive-that is just the blood draw. In addition to the diagnosis mentioned above, cancer biomarkers have diverse application in monitoring of diseases progression, treatment evaluation and identification of therapeutic targets. The health care providers can monitor changes in the level of biomarkers over time to assess the effectiveness of treatments hence make necessary changes in the treatments. Biomarkers are also capable of diagnosing at-risk patients to develop or recur cancer so that appropriate preventive and surveillance strategies can be carried out on them. The Asia-Pacific region is steadily increasing its demand for cancer biomarkers: incidence of the disease, awareness of early stages, and scientific advancement. And because of a huge population and increasing healthcare infrastructure, the industry would grow in that region. Scientific innovation and interactions between researchers, health providers, and industrialists are enhancing the development of new biomarkers at a faster rate. The Asia-Pacific Cancer Biomarkers Industry is one of the most vibrant sectors with vast potential. Biomarkers for cancer are a very significant tool in the early detection, diagnosis, and management of cancer. Given that this region continues to invest in more research and development, we can expect further advancements into biomarker technology, yielding far better outcomes for the patients suffering from cancer. Recent developments include: October 2022: The Garvan Institute of Medical Research in Australia discovered a new biomarker for prostate cancer that could lead to better diagnosis and treatment for men with the aggressive form of this disease., February 2022: The University of South Australia used novel biomarkers to decode metastatic breast cancer. They found a connection between aggressive breast cancer cells and the dual CXCR4-CCR7 cell surface protein complexes.. Key drivers for this market are: Rising Prevalence of Cancer, Increasing Research Activities and Growing Usage of Biomarkers in Drug Development. Potential restraints include: High Cost of Diagnosis, Reimbursement Issues. Notable trends are: Breast Cancer is Expected to Grow with a Significant CAGR in the Market Over the Forecast Period.

This dataset presents the footprint of female cancer mortality statistics in Australia for all cancers combined and the 11 top cancer groupings (breast, cervical, colorectal, leukaemia, lung, lymphoma, melanoma of the skin, ovary, pancreas, thyroid and uterus) and their respective ICD-10 codes. The data spans the years 2009-2013 and is aggregated to Greater Capital City Statistical Areas (GCCSA) from the 2011 Australian Statistical Geography Standard (ASGS).

Mortality data refer to the number of deaths due to cancer in a given time period. Cancer deaths data are sourced from the Australian Institute of Health and Welfare (AIHW) 2013 National Mortality Database (NMD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Institute of Health and Welfare - 2013 National Mortality Database.

Please note:

• AURIN has spatially enabled the original data.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a GCCSA. The number of people who could not be assigned a GCCSA is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• Cause of Death Unit Record File data are provided to the AIHW by the Registries of Births, Deaths and Marriages and the National Coronial Information System (managed by the Victorian Department of Justice) and include cause of death coded by the Australian Bureau of Statistics (ABS). The data are maintained by the AIHW in the NMD.

• Year refers to year of occurrence of death for years up to and including 2012, and year of registration of death for 2013. Deaths registered in 2011 and earlier are based on the final version of cause of death data; deaths registered in 2012 and 2013 are based on revised and preliminary versions, respectively and are subject to further revision by the ABS.

• Cause of death information are based on underlying cause of death and are classified according to the International Classification of Diseases and Related Health Problems (ICD). Deaths registered in 1997 onwards are classified according to the 10th revision (ICD-10).

• Colorectal deaths presented are underestimates. For further information, refer to "Complexities in the measurement of bowel cancer in Australia" in Causes of Death, Australia (ABS cat. no. 3303.0).

According to Cognitive Market Research, the Global Tumor Ablation Market Size was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

• The global Tumor Ablation Market will expand significantly by XX% CAGR between 2024 and 2031. • The radiofrequency tumor ablation segment held the largest share. The dominance can be attributed to its advantages, such as specificity and efficiency in solid tumor ablation procedures in the kidney and liver. • The percutaneous ablation segment accounted for the highest market share during the forecast period. These procedures provide a better security, quicker recovery, and less scarring • Liver cancer dominates the global tumor ablation market, largely due to the high incidence and mortality rates associated with this disease. • Hospitals constitute a significant share of the market due to their comprehensive healthcare services and accessibility to a wide patient demographic. Based on type, demand for Tumor Ablation Devices is increasing. • The North america accounted for the highest market share in the Global Tumor Ablation Market. CURRENT SCENARIO OF THE TUMOR ABLATION MARKET

Driving Factors of Tumor Ablation Market

Tumor Ablation Market Growth is Driven by an Increase in Cancer Prevalence 

Cancer is a globally prevalent disease and a leading cause of death worldwide. For example, the Cancer Australia Statistics for 2022 reported 162,163 new cancer cases diagnosed in Australia, emphasizing the substantial burden it poses. (Source:https://www.canceraustralia.gov.au/impacted-cancer/what-cancer/cancer-australia-statistics)

Similarly, McMillan Cancer Support's October 2022 update revealed that 3 million people were living with cancer in the UK, with projections indicating a steady increase in this number over the coming years. (Source:https://www.macmillan.org.uk/about-us/what-we-do/research/cancer-statistics-fact-sheet)

The market for Tumor ablation is expected to increase as a result of the increasing need for operations and efficient ablation techniques brought about by the rising incidence of cancer. The incidence of cancer has increased due to a sharp rise in the world's senior population as well as harmful modern lifestyles in all age categories. The market for Tumor ablation is becoming more lucrative due to rising costs associated with cancer treatment.

According to data publicly available by WHO, the disease accounts for nearly one in six deaths. WHO further mentions that cancer-causing infections such as hepatitis made up nearly one-third of cancer cases in the global South.

In the U.S., National Cancer Institute forecasted that national estimates of cancer care costs are expected to rise to as high as US$ 173 Bn in 2020. (Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107566/#:~:text=Contribution,increase%20of%2039%25%20from%202010.)

The need for ablation technologies to treat kidney, soft tissue, liver, and bone malignancies is predicted to rise in tandem with the rising incidence of lung, prostate, colon, and breast cancer. Focus on cancer treatment is increasing market income for Tumor ablation.

For instance, in September 2023, the Government of Canada reported that about 28,600 Canadian women were diagnosed with breast cancer in 2022,i.e., 25% of all new cancer cases in women in 2022. (Source:https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/breast-cancer.html)

As a result, the rising global prevalence of cancer is expected to provide considerable growth prospects for market players over the forecast period.

Increasing patients and surgeons’ inclination towards minimally invasive procedures will drive the growth of the market

Smaller incisions or needle insertions are the hallmark of minimally invasive procedures, which have a number of benefits over open surgery. Minimal tissue injury, less blood loss, and a decreased chance of complications are the outcomes of these operations. Minimally invasive surgery patients usually recover more quickly from their procedures and spend less time in the hospital afterward, which improves their quality of life overall and enables them t...

Medical Mammography Equipment Market Outlook

The global medical mammography equipment market size was valued at approximately USD 2.1 billion in 2023 and is projected to reach USD 3.9 billion by 2032, growing at a CAGR of 6.5% during the forecast period. This notable growth is primarily driven by advancements in imaging technologies, increased awareness about early breast cancer detection, and rising government initiatives for cancer screening programs.

One of the primary growth factors in the medical mammography equipment market is the increasing prevalence of breast cancer worldwide. Breast cancer remains one of the most common cancers affecting women, and early detection is crucial for effective treatment and improved survival rates. Mammography is considered the gold standard for breast cancer screening, which has led to a significant rise in its adoption. Moreover, advancements in digital technologies and the development of 3D mammography, also known as breast tomosynthesis, have further enhanced the accuracy and efficiency of breast cancer diagnosis, driving market growth.

Technological advancements in mammography equipment have also played a significant role in market expansion. The transition from analog to digital mammography has revolutionized breast imaging by providing higher resolution images, reducing radiation exposure, and enabling better storage and retrieval of patient data. Additionally, the advent of 3D mammography has addressed many limitations of traditional 2D mammography by offering more detailed images and reducing false positives and call-back rates. These innovations have significantly improved the diagnostic capabilities of healthcare providers, further boosting the demand for advanced mammography equipment.

Government initiatives and screening programs are another critical factor contributing to the growth of the medical mammography equipment market. Many countries have implemented national breast cancer screening programs to facilitate early detection and improve patient outcomes. For instance, programs such as BreastScreen Australia, the National Breast Screening Program in the UK, and the Breast Cancer Screening Program in the US have significantly increased the adoption of mammography equipment. These initiatives, coupled with rising awareness campaigns, have encouraged more women to undergo regular screenings, thus driving market growth.

Mammography, as a critical tool in breast cancer screening, has evolved significantly over the years. It remains the cornerstone of early detection strategies, offering a non-invasive method to identify potential abnormalities in breast tissue. The process involves using low-dose X-rays to create detailed images of the breast, which radiologists analyze for any signs of cancer. With the advent of digital technologies, mammography has become more efficient, providing clearer images and reducing the need for repeat scans. This evolution not only enhances diagnostic accuracy but also increases patient comfort and reduces anxiety associated with the screening process.

Regionally, the market for medical mammography equipment is witnessing significant growth across various geographies. North America holds the largest market share, attributed to the high prevalence of breast cancer, well-established healthcare infrastructure, and extensive government support for breast cancer screening programs. Europe follows closely, driven by similar factors and a growing emphasis on early diagnosis. The Asia Pacific region is expected to exhibit the highest growth rate during the forecast period, fueled by increasing awareness, rising healthcare expenditure, and expanding screening initiatives in countries like China and India. Latin America and the Middle East & Africa are also anticipated to experience steady growth, supported by improving healthcare infrastructure and growing awareness about breast cancer detection.

Product Type Analysis

In the product type segment, digital mammography stands out as the most significant contributor to the medical mammography equipment market. Digital mammography, which includes Full Field Digital Mammography (FFDM), offers superior image quality, reduced radiation dose, and enhanced diagnostic accuracy compared to analog systems. The transition from analog to digital has been a game-changer, enabling healthcare providers to detect breast cancer at earlier stages, thus improving treatment outcomes. The convenience of storing and sharing digital images also provides an

Yearly citation counts for the publication titled "The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes".

In 2023, an estimated 3,255 females and 36 males died from breast cancer in Australia. Overall, the number of deaths from breast cancer among males and females in Australia has trended upwards over time since 1978.

Lung Cancer: Largest indication segment due to high cancer incidence and availability of targeted therapies.Breast Cancer: Second-largest segment with growing demand for adjuvant therapies.Colorectal Cancer: Growing segment due to earlier detection and advancements in surgical and medical treatments. Recent developments include: May 2023 Sun Pharma entered into a license agreement with Philogen SpA (Italy) for commercializing Philogen’s specialty cancer product, Nidlegy (Daromun) in Australia, Europe, and New Zealand. As per the agreement Sun Pharma holds exclusive rights to marketing Nidlegy for skin cancer in Europe, New Zealand, and Australia., January 2023, Dr. Reddy's Laboratories announced the acquisition trademark rights of the breast cancer drug Primcyv (Palbociclib) from Pfizer. As per the agreement company Dr.Reddy manufactured cancer API in its production facility which is approved by US FDA., December 2021, Biocon partnered with Tabuk Pharmaceuticals (Saudi Arabia) to provide its specialty generic drugs in the Middle East. The partnership will allow Biocon access to the MENA region, which now encompasses Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. Key drivers for this market are: INCREASING DEMAND FOR NEWLY DEVELOPED SMALL MOLECULE DRUGS, RISING PREVALENCE OF CANCER; GROWING TREND OF PHARMACEUTICAL OUTSOURCING. Potential restraints include: STRINGENT REGULATORY REQUIREMENTS. Notable trends are: increasing demand for newly developed small molecule drugs.

The number of potentially avoidable deaths and their cause at age 0 to 74 years with corresponding mortality rates/ratios with respective confidence intervals, 2010 - 2014. The specified causes of death are: cancers, colorectal cancer, breast cancer, circulatory system diseases, ischaemic heart disease, cerebrovascular disease, respiratory system diseases, chronic obstructive pulmonary disease, deaths from select external causes of mortality, suicide and self-inflicted injuries, other external causes of mortality, transport accidents. (all entries that were classified as not shown, not published or not applicable were assigned a null value; no data was provided for Maralinga Tjarutja LGA, in South Australia). The data is by LGA 2015 profile (based on the LGA 2011 geographic boundaries). For more information on statistics used please refer to the PHIDU website, available from: http://phidu.torrens.edu.au/. For information on the avoidable mortality concept please refer to the Australian and New Zealand Atlas of Avoidable Mortality, available from: http://phidu.torrens.edu.au/. Source: Data compiled by PHIDU from deaths data based on the 2010 to 2014 Cause of Death Unit Record Files supplied by the Australian Coordinating Registry and the Victorian Department of Justice, and ABS Estimated Resident Population (ERP), 30 June 2010 to 30 June 2014.